Search Results - hiv%2faids

Improved CD-4 Mimetic Compounds HIV Treatment

Indoline core CD-4 mimetics are a HIV treatment that trick the virus into entering a vulnerable “open” conformation, allowing antibody-dependent cellular toxicity.

Published: 6/25/2026

Small-Molecule Therapeutic for Stabilizing HIV-1 Envelope Proteins to Increase Immune Response

Small-molecule inhibitor that prolongs exposure of HIV-1 to broadly neutralizing antibodies to suppress viral entry and infection

Published: 6/25/2026

Inventor(s):

Amos Smith, Althea Lang, Joseph Sodroski

Keywords(s):

Drug Target, HIV/AIDS, Immunology, Infectious Disease

Category(s):

Technology Classifications > Therapeutics, Technology Classifications > Chemical Processes and Synthesis

Small Molecules That Expose HIV Env Sites To Trigger Targeted Immune Killing

This technology uses small molecules to bind HIV Env on infected cells, expose hidden sites, and trigger ADCC, enabling the immune system to kill cells that current therapies cannot reach. By improving antibody recognition and reducing infectious virus production, it provides a complementary approach that directly targets infected cells rather than only preventing new infections.

Published: 12/1/2025

Inventor(s):

Amos Smith, Melissa Grenier-Davies, Andres Finzi, Jean-Philippe Chapleau, Shilei Ding

Keywords(s):

HIV/AIDS

Category(s):

Technology Classifications > Therapeutics, Technology Classifications > Vaccines

A Potent HIV Treatment with Low Toxicity

A small-molecule class that binds to HIV particles to improve immune response and block viral entry into cells.

Published: 11/11/2025

Inventor(s):

Amos Smith, Xuchen Zhao, Tyler Higgins, Andres Finzi, Shilei Ding, Daniel Lee, Marzena Pazgier, Dung Nguyen, William Tolbert

Keywords(s):

Drug Target, HIV/AIDS, Small Molecule, Soft Materials

Category(s):

Technology Classifications > Chemical Processes and Synthesis, Technology Classifications > Therapeutics

Methods and Sequences for mRNA and Other HIV Vaccine Development

Unique sequences eliciting broadly neutralizing antibodies (bNAbs) against human immunodeficiency virus (HIV) that could be used to develop effective mRNA-based and other types of HIV vaccine.